What is a stock summary page? Click here for an overview.
Business Description
ImmuCell Corp
NAICS : 325412
SIC : 2834
ISIN : US4525253062
Description
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.24 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.56 | |||||
| Debt-to-EBITDA | 39.83 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.55 | |||||
| Beneish M-Score | -2.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2 | |||||
| 3-Year EPS without NRI Growth Rate | -44.7 | |||||
| 3-Year FCF Growth Rate | -30.5 | |||||
| 3-Year Book Growth Rate | -6.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.15 | |||||
| 9-Day RSI | 47.55 | |||||
| 14-Day RSI | 46.98 | |||||
| 3-1 Month Momentum % | 8.89 | |||||
| 6-1 Month Momentum % | 42.21 | |||||
| 12-1 Month Momentum % | -4.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Days Inventory | 146.01 | |||||
| Days Sales Outstanding | 30.12 | |||||
| Days Payable | 14.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | -3.9 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 29.97 | |||||
| Operating Margin % | -6.19 | |||||
| Net Margin % | -8.14 | |||||
| FCF Margin % | -2.68 | |||||
| ROE % | -8.49 | |||||
| ROA % | -4.94 | |||||
| ROIC % | -4.16 | |||||
| 3-Year ROIIC % | -45.45 | |||||
| ROC (Joel Greenblatt) % | -4.14 | |||||
| ROCE % | -4.04 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.56 | |||||
| PB Ratio | 1.6 | |||||
| Price-to-Tangible-Book | 1.6 | |||||
| EV-to-EBIT | -33.78 | |||||
| EV-to-EBITDA | 140.66 | |||||
| EV-to-Revenue | 2.07 | |||||
| EV-to-FCF | -78.24 | |||||
| Price-to-GF-Value | 0.64 | |||||
| Price-to-Median-PS-Value | 0.6 | |||||
| Earnings Yield (Greenblatt) % | -2.96 | |||||
| FCF Yield % | -1.62 | |||||
| Forward Rate of Return (Yacktman) % | 10.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ICCC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ImmuCell Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 26.494 | ||
| EPS (TTM) ($) | -0.29 | ||
| Beta | 0.3 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.35 | ||
| Volatility % | 42.01 | ||
| 14-Day RSI | 46.98 | ||
| 14-Day ATR ($) | 0.271421 | ||
| 20-Day SMA ($) | 5.03874 | ||
| 12-1 Month Momentum % | -4.02 | ||
| 52-Week Range ($) | 3.34 - 5.82 | ||
| Shares Outstanding (Mil) | 8.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImmuCell Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ImmuCell Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ImmuCell Corp Frequently Asked Questions
What is ImmuCell Corp(ICCC)'s stock price today?
The current price of ICCC is $4.94. The 52 week high of ICCC is $5.82 and 52 week low is $3.34.
When is next earnings date of ImmuCell Corp(ICCC)?
The next earnings date of ImmuCell Corp(ICCC) is 2025-05-14 Est..
Does ImmuCell Corp(ICCC) pay dividends? If so, how much?
ImmuCell Corp(ICCC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers